Point72 Asset Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Point72 Asset Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,471,771	Closed	-$3.16M	–	2555
2024 Q3	$3.16M	Hold	1,471,771	–	–	0.01%	1019
2024 Q2	$7.59M	Hold	1,471,771	–	–	0.02%	715
2024 Q1	$7.87M	Hold	1,471,771	–	–	0.02%	807
2023 Q4	$11.5M	Buy	+1,471,771	New	+$5.04M	0.03%	638
2020 Q4	–	Sell	-65,799	Closed	-$5.82M	–	1182
2020 Q3	$5.82M	Sell	65,799 -87,593	-57%	-$9.95M	0.03%	529
2020 Q2	$16.4M	Sell	153,392 -74,108	-33%	-$6.65M	0.11%	244
2020 Q1	$13.5M	Buy	+227,500	New	+$15.4M	0.11%	265
2019 Q1	–	Sell	-24,000	Closed	-$1.34M	–	1277
2018 Q4	$1.34M	Buy	24,000 +15,816	+193%	+$1.2M	0.01%	773
2018 Q3	$975K	Sell	8,184 -8,496	-51%	-$985K	﹤0.01%	852
2018 Q2	$1.7M	Buy	+16,680	New	+$2.07M	0.01%	773

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Point72 Asset Management's SYRS Position: Q4 2024 in Review

Point72 Asset Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 1,471,771 shares — an estimated $3.16M sold.

Point72 Asset Management first reported a position in SYRS in Q2 2018 and held it in 10 quarters. The position peaked at $16.4M in Q2 2020. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

Point72 Asset Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Point72 Asset Management sold 1,471,771 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $3.16M.
Point72 Asset Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 10 quarters.
Point72 Asset Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $16.4M in Q2 2020.
44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Point72 Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.